Rheumatology - McMaster Experts

publication venue for

Ocular manifestations of ANCA-associated vasculitis 2023
Causal pathways to health-related quality of life in children with juvenile idiopathic arthritis: results from the ReACCh-Out cohort 2021
Subglottic stenosis and endobronchial disease in granulomatosis with polyangiitis 2019
A CLINICAL SCORING SYSTEM FOR RISK STRATIFICATION OF GIANT CELL ARTERITIS 2019
DIFFUSE ALVEOLAR HEMORRHAGE, PULMONARY NODULES AND INFILTRATES IN GRANULOMATOSIS POLYANGIITIS AND MICROSCOPIC POLYANGIITIS. A COHORT STUDY OF 736 PATIENTS 2019
FACTORS ASSOCIATED WITH DISEASE PROGRESSION IN PATIENTS WITH MYELOPEROXIDASE-ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-RELATED PULMONARY FIBROSIS 2019
GENETIC EVIDENCE OF EOSINOPHIL NUMBER UNDERPINNING PR3-AAV AND PLAUSIBLE HOST GENETIC PREDISPOSITION TO MICROBIAL DRIVERS OF DISEASE 2019
THE EFFECT OF PLASMA EXCHANGE ON END-STAGE RENAL DISEASE AND DEATH IN PATIENTS WITH SEVERE ANCA-ASSOCIATED VASCULITIS 2019
THE EFFECT OF REDUCED-DOSE ORAL GLUCOCORTICOIDS DURING INDUCTION OF REMISSION INDUCTION IN SEVERE ANCA-ASSOCIATED VASCULITIS 2019
UTILIZATION OF CANADIAN HEALTHCARE ADMINISTRATIVE DATABASES TO ACCURATELY IDENTIFY CASES OF ANCA-ASSOCIATED VASCULITIS 2019
VERITAS: VASCULITIS: EFFECTS OF REMISSION MAINTENANCE THERAPIES ON RELAPSE AND SIDE EFFECTS ON PATIENT PREFERENCES: A STUDY PROTOCOL 2019
A RANDOMIZED DOUBLE-BLIND TRIAL OF ABATACEPT AND GLUCOCORTICOIDS FOR THE TREATMENT OF TAKAYASU'S ARTERITIS 2017
ARTERIAL LESIONS IN GIANT CELL ARTERITIS 2017
DEMOGRAPHIC CHARACTERISTICS OF JAPANESE PARTICIPANTS IN PEXIVAS AS COMPARED WITH REMIT-JAV 2017
DISCREPANCIES BETWEEN CLINICAL- AND IMAGING-BASED ASSESSMENTS OF DISEASE ACTIVITY IN TAKAYASU'S ARTERITIS 2017
IDENTIFICATION OF FUNCTIONAL AND EXPRESSION POLYMORPHISMS ASSOCIATED WITH RISK FOR ANTI-NEUTROPHIL CYTOPLASMIC AUTOANTIBODY-ASSOCIATED VASCULITIS 2017
LATE-ONSET RELAPSE IN PATIENTS WITH SYSTEMIC VASCULITIS 2017
PATIENT REPORTED OUTCOMES AS PREDICTORS OF FLARES IN TAKAYASU ARTERITIS 2017
PLASMA EXCHANGE AND GLUCOCORTICOID DOSING IN THE TREATMENT OF ANTI-NEUTROPHIL CYTOPLASM ANTIBODY ASSOCIATED VASCULITIS: BASELINE CHARACTERISTICS OF A RANDOMIZED CONTROLLED TRIAL (PEXIVAS) 2017
PREVALENCE OF IMMUNOFLUORESCENT DEPOSITS IN ANCA ASSOCIATED VASCULITIS 2017
SPUTUM ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODIES (ANCA) IN EOSINOPHILIC GRANULAMATOSIS AND POLYANGIITIS (EGPA) 2017
THE STEROID TAPERING IN ANCA VASCULITIS EVALUATION STUDY (STAVE) 2: A SYSTEMATIC REVIEW AND META-ANALYSIS 2017
TWO INTERNATIONAL MULTIREGIONAL INVESTIGATOR INITIATED CLINICAL TRIALS ON VASCULITIS: COLLABORATION WITH EUVAS, VCRC AND NATIONWIDE VASCULITIS STUDY GROUPS OF JAPAN 2017
URINARY EPIDERMAL GROWTH FACTOR AS A BIOMARKER OF RENAL INVOLVEMENT IN ANCA-ASSOCIATED VASCULITIS 2017
UTILITY OF MEASUREMENTS OF URINARY SOLUBLE CD163 & MCP1 IN THE IDENTIFICATION OF SUBTLE RENAL FLARES IN ANCA VASCULITIS 2017
Gout in paleopathology; The elusive nature of urate 2007
Lung imaging patterns in connective tissue disease–associated interstitial lung disease impact prognosis and immunosuppression response. 63:2734-2740. 2024
Vessel wall MRI in giant cell arteritis: standardized protocol and scoring approach developed by an international working group.. keae498. 2024
A decade of progress in juvenile idiopathic arthritis treatments and outcomes in Canada: results from ReACCh-Out and the CAPRI registry. 63:SI173-SI179. 2024
Assessment of damage in Takayasu’s arteritis. keae333. 2024
The effect of antimalarials on the safety and persistence of treatment with biologic agents or Janus kinase inhibitors in rheumatoid arthritis. 63:456-465. 2024
Stricter treat-to-target in RA does not result in less radiographic progression: a longitudinal analysis in RA BIODAM. 62:2989-2997. 2023
CanVasc consensus recommendations for the use of avacopan in antineutrophil cytoplasm antibody-associated vasculitis: 2022 addendum. 62:2646-2651. 2023
Added diagnostic yield of temporal artery magnetic resonance angiography in the evaluation of giant cell arteritis. 62:2197-2202. 2023
Comment on: Text neck misdiagnosed as fibromyalgia.. 62:e199-e200. 2023
Comparing Canadian paediatric rheumatology practice to the 2019 ACR Juvenile Idiopathic Arthritis guidelines: results from the CAPRI Registry. 62:1616-1620. 2023
Validation of the parent global assessment as a health-related quality of life measure in juvenile idiopathic arthritis: results from ReACCh-Out. 62:SI152-SI162. 2023
Trends in risk factor control in patients with gout: data from the National Health and Nutrition Examination Survey, 2007–2018. 62:158-168. 2022
Hypothyroidism in vasculitis. 61:2942-2950. 2022
Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey. 61:SI143-SI150. 2022
Impact of the COVID-19 pandemic on juvenile idiopathic arthritis presentation and research recruitment: results from the CAPRI registry. 61:SI157-SI162. 2022
Incidence of chronic immune-mediated inflammatory diseases after diagnosis with Kawasaki disease: a population-based cohort study. 61:2095-2103. 2022
Impact of the COVID-19 Pandemic on Juvenile Idiopathic Arthritis Presentation and Research Recruitment: Results from the CAPRI Registry (135/140).. 49:800-800. 2021
Contextualizing temporal arterial magnetic resonance angiography in the diagnosis of giant cell arteritis: a retrospective cohort study. 60:4229-4237. 2021
Comment on: Influence of prior antibiotic use on risk of rheumatoid arthritis: case–control study in general practice. Reply. 60:e150-e150. 2021
Association between age at disease onset of anti-neutrophil cytoplasmic antibody–associated vasculitis and clinical presentation and short-term outcomes. 60:617-628. 2021
Response to placebo in non-renal, non-neuropsychiatric systemic lupus erythematosus: a systematic review and pooled analysis. 60:73-80. 2021
Long-term outcomes and disease course of children with juvenile idiopathic arthritis in the ReACCh-Out cohort: a two-centre experience. 59:3727-3730. 2020
Patients’ attitudes and experiences of transition from paediatric to adult healthcare in rheumatology: a qualitative systematic review. 59:3737-3750. 2020
Corrigendum to: Incidence and prevalence of giant cell arteritis in Ontario, Canada. 59:3584-3584. 2020
Incidence and prevalence of giant cell arteritis in Ontario, Canada. 59:3250-3258. 2020
A new Canadian inception cohort for juvenile idiopathic arthritis: The Canadian Alliance of Pediatric Rheumatology Investigators Registry. 59:2796-2805. 2020
Influence of prior antibiotic use on risk of rheumatoid arthritis: case control study in general practice. 59:1281-1287. 2020
Derivation of an angiographically based classification system in Takayasu’s arteritis: an observational study from India and North America. 59:1118-1127. 2020
Changes in skin score in early diffuse cutaneous systemic sclerosis are associated with changes in global disease severity. 59:398-406. 2020
Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality. 58:636-644. 2019
020. IDENTIFICATION OF TARGET ANTIGENS FOR ANTI-ENDOTHELIAL CELL ANTIBODIES IN PATIENTS WITH TAKAYASU’S ARTERITIS USING PROTEOMICS. 58:kez057.019. 2019
035. CANDIDATE BIOMARKERS IN ANCA-ASSOCIATED VASCULITIS IDENTIFIED USING A PROTEOMIC APPROACH. 58:kez057.034. 2019
043. SUBGLOTTIC STENOSIS AND ENDOBRONCHIAL DISEASE IN GRANULOMATOSIS WITH POLYANGIITIS. 58:kez057.042. 2019
045. EVALUATION OF NOVEL SERUM BIOMARKERS OF DISEASE ACTIVITY IN GIANT CELL ARTERITIS, TAKAYASU’S ARTERITIS, POLYARTERITIS NODOSA, AND EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS. 58:kez057.044. 2019
083. COMPARISON OF ARTERIAL PATTERNS OF DISEASE IN TAKAYASU’S ARTERITIS AND GIANT CELL ARTERITIS. 58:kez058.023. 2019
084. DISCOVERY AND VALIDATION OF A NOVEL ANGIOGRAPHIC CLASSIFICATION SCHEME IN TAKAYASU’S ARTERITIS. 58:kez058.024. 2019
090. A CLINICAL SCORING SYSTEM FOR RISK STRATIFICATION OF GIANT CELL ARTERITIS. 58:kez058.030. 2019
138. DIFFUSE ALVEOLAR HEMORRHAGE, PULMONARY NODULES AND INFILTRATES IN GRANULOMATOSIS POLYANGIITIS AND MICROSCOPIC POLYANGIITIS. A COHORT STUDY OF 736 PATIENTS. 58:kez059.015. 2019
139. UTILIZATION OF CANADIAN HEALTHCARE ADMINISTRATIVE DATABASES TO ACCURATELY IDENTIFY CASES OF ANCA-ASSOCIATED VASCULITIS. 58:kez059.016. 2019
148. SHORT-FORM 36 AS A MEASURE OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH GIANT CELL ARTERITIS. 58:kez059.025. 2019
160. VERITAS: VASCULITIS: EFFECTS OF REMISSION MAINTENANCE THERAPIES ON RELAPSE AND SIDE EFFECTS ON PATIENT PREFERENCES: A STUDY PROTOCOL. 58:kez059.037. 2019
275. FACTORS ASSOCIATED WITH DISEASE PROGRESSION IN PATIENTS WITH MYELOPEROXIDASE-ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-RELATED PULMONARY FIBROSIS. 58:kez062.049. 2019
Renal relapse in antineutrophil cytoplasmic autoantibody-associated vasculitis: unpredictable, but predictive of renal outcome. 58:103-109. 2019
Treatment of small intestinal bacterial overgrowth in systemic sclerosis: a systematic review. 57:1802-1811. 2018
The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. 57:1623-1631. 2018
Evaluation of damage in giant cell arteritis. 57:322-328. 2018
Evaluating the design and reporting of pragmatic trials in osteoarthritis research. 57:59-63. 2018
Predictive value of European Scleroderma Group Activity Index in an early scleroderma cohort. 56:1111-1122. 2017
The effect of rheumatoid arthritis–associated autoantibodies on the incidence of cardiovascular events in a large inception cohort of early inflammatory arthritis. 56:kew474-kew474. 2017
Clinical correlates of faecal incontinence in systemic sclerosis: identifying therapeutic avenues. 56:kew441-kew441. 2017
P1_185 The Steroid Tapering in ANCA Vasculitis Evaluation Study (STAVE) 2: a Systematic Review and Meta-Analysis. 56:iii103-iii103. 2017
WS1_1 Sputum Anti-neutrophil Cytoplasmic Antibodies (ANCA) in Eosinophilic Granulamatosis and Polyangiitis (eGPA). 56:iii17-iii19. 2017
BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics. 56:313-316. 2017
Calcinosis is associated with digital ischaemia in systemic sclerosis—a longitudinal study. 55:2148-2155. 2016
Self-reported comorbidity is common in early inflammatory arthritis and associated with poorer function and worse arthritis disease outcomes: results from the Canadian Early Arthritis Cohort. 55:1751-1762. 2016
Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis. 54:1351-1359. 2015
Comment on: A critical evaluation of the trigger point phenomenon. 54:1126-1127. 2015
What drives the comparative effectiveness of biologics vs methotrexate in rheumatoid arthritis? Meta-regression and graphical inspection of suspected clinical factors. 53:1264-1273. 2014
Are there differences between young- and older-onset early inflammatory arthritis and do these impact outcomes? An analysis from the CATCH cohort. 53:1075-1086. 2014
The prevalence of vertebral fracture on vertebral fracture assessment imaging in a large cohort of patients with rheumatoid arthritis. 53:821-827. 2014
Unilateral vs bilateral symptomatic knee osteoarthritis: associations between pain intensity and function. 52:2229-2237. 2013
All-cause hospitalizations in systemic lupus erythematosus from a large Canadian referral centre. 52:905-909. 2013
Increased production of IL-5 and dominant Th2-type response in airways of Churg–Strauss syndrome patients. 51:1887-1893. 2012
von Willebrand factor antigen--a possible biomarker of disease activity in childhood central nervous system vasculitis?. 51:1838-1845. 2012
Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. 51:571-576. 2012
Association of myocardial infarctions with COX-2 inhibition may be related to immunomodulation towards a Th1 response resulting in atheromatous plaque instability: an evidence-based interpretation. 49:837-843. 2010
Investigating the role of the interleukin-23/-17A axis in rheumatoid arthritis. 48:1581-1589. 2009
Intrinsic pathway of apoptosis in peripheral blood eosinophils of Churg–Strauss syndrome. 48:1202-1207. 2009
Reports of abnormal cervical cancer screening tests in systemic sclerosis. 48:149-151. 2009
Quality of randomized clinical trials in juvenile idiopathic arthritis. 47:640-645. 2008
Arthritis risk after acute bacterial gastroenteritis. 47:200-204. 2008
Developing a disease activity tool for systemic-onset juvenile idiopathic arthritis by international consensus using the Delphi approach. 44:1574-1578. 2005
What does ‘active disease’ mean? patient and parent perceptions of disease activity in the systemic arthritis form of juvenile idiopathic arthritis (SO-JIA). 44:796-799. 2005
Acupuncture for the alleviation of lateral epicondyle pain: a systematic review. 43:1085-1090. 2004
Safety of tacrolimus in patients with rheumatoid arthritis: long-term experience. 43:992-999. 2004
Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate. 43:712-718. 2004
Doctor-patient communication in a musculoskeletal unit: relationship between an observer-rated structured scoring system and patient opinion. 42:1518-1522. 2003
Inaccuracy in the diagnosis of fibromyalgia syndrome: analysis of referrals. 42:263-267. 2003
Stevens-Johnson syndrome in association with hydroxychloroquine treatment for rheumatoid arthritis. 41:A473-474. 2002
Characteristics of septic arthritis in human immunodeficiency virus- infected haemophiliacs versus other risk groups. 38:139-142. 1999
Auranofin. 36:560-572. 1997
Salmon calcitonin nasal spray in the prevention of corticosteroid- induced osteoporosis. 36:255-259. 1997
SENSITIVITY AND SPECIFICITY OF DIFFERENT DIAGNOSTIC CRITERIA FOR BEHÇET'S DISEASE ACCORDING TO THE LATENT CLASS APPROACH. 34:932-935. 1995
Cyclosporin A nephropathy in patients with rheumatoid arthritis.. 32 Suppl 1:60-64. 1993
Successful Treatment of Gold-induced Aplastic Anaemia with Granulocyte Macrophage Colony Stimulating Factor. 31:428-429. 1992
Prior Score Availability: Observations Using The WOMAC Osteoarthritis Index. 30:150-151. 1991
INTERACTION OF IBUPROFEN AND WARFARIN ON PRIMARY HAEMOSTASIS. 28:46-49. 1989
PUNCHED-CARD AID IN RHEUMATOLOGICAL DIAGNOSIS. 26:46-50. 1987

Rheumatology Journal

Overview

publication venue for

has subject area

Identity

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)